Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy

Authors: Marcel Roos, Dimitrios Oikonomou, Maximilian von Eynatten, Peter B Luppa, Uwe Heemann, Jens Lutz, Marcus Baumann, Peter P Nawroth, Angelika Bierhaus, Per M Humpert

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients with type 2 diabetes mellitus and early diabetic nephropathy.

Methods

Fetuin-A serum levels were assessed by ELISA in a cross-sectional setting in 153 patients with type 2 diabetes. Associations of fetuin-A with metabolic, inflammatory and vascular markers were studied. Atherosclerotic burden was assessed by ankle-brachial-index (ABI) as well as detection of common carotid artery intima-media thickness (IMT).

Results

Levels of fetuin-A were lower in male than in female patients (0.49 ± 0.15 vs. 0.56 ± 0.20 g/L, p = 0.02). In addition, there was an inverse correlation with age (r = -0.20, P = 0.01). Bivariate correlations adjusted for age and gender revealed no significant correlations with metabolic parameters, except for a weak inverse correlation with serum adiponectin (r = -0.19, p = 0.02). Regarding parameters of micro- and macrovascular disease, fetuin-A was significantly associated with ABI (r = 0.18, p = 0.04), while there was no association with IMT (r = -0.07, p = n.s). Patients with an ABI < 0.9 had lower fetuin A levels than patients with an ABI 0.9-1.3 or > 1.3 (0.43 ± 0.10 vs. 0.52 ± 0.17 vs. 0.54 ± 0.18 g/L p = 0.05). Neither GFR nor albuminuria were associated with fetuin-A serum levels. Patients with prevalent neuropathy did not have altered fetuin-A levels compared to diabetic controls. In step-wise logistic regression analysis including age, gender, HbA1c, total cholesterol, glomerular filtration rate and fetuin-A, only total cholesterol (β = 0.01, p = 0.02) and fetuin-A (β = -5.99, p = 0.03) proved to be independent predictors of an ABI < 0.9.

Conclusions

The results of this cross-sectional study suggest that lower fetuin-A levels are associated with macrovascular late complications in high-risk type 2 diabetes patients while there are no associations of fetuin-A with metabolic status or microvascular complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference St Clair L, Ballantyne CM: Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol. 2007, 99: 80B-88B. 10.1016/j.amjcard.2006.11.008.CrossRefPubMed St Clair L, Ballantyne CM: Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol. 2007, 99: 80B-88B. 10.1016/j.amjcard.2006.11.008.CrossRefPubMed
2.
go back to reference Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008, 358: 2107-2116. 10.1056/NEJMoa0707064.CrossRefPubMed Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008, 358: 2107-2116. 10.1056/NEJMoa0707064.CrossRefPubMed
3.
go back to reference Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006, 166: 1368-1373. 10.1001/archinte.166.13.1368.CrossRefPubMed Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006, 166: 1368-1373. 10.1001/archinte.166.13.1368.CrossRefPubMed
4.
go back to reference Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG: Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol. 2010, 55: 2080-2091. 10.1016/j.jacc.2009.12.047.CrossRefPubMed Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG: Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol. 2010, 55: 2080-2091. 10.1016/j.jacc.2009.12.047.CrossRefPubMed
5.
go back to reference Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin A. Formation of colloidal calciprotein particles. J Biol Chem. 2003, 278: 13333-13341. 10.1074/jbc.M210868200.CrossRefPubMed Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin A. Formation of colloidal calciprotein particles. J Biol Chem. 2003, 278: 13333-13341. 10.1074/jbc.M210868200.CrossRefPubMed
6.
go back to reference Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glyco-protein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003, 112: 357-366.PubMedCentralCrossRefPubMed Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glyco-protein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003, 112: 357-366.PubMedCentralCrossRefPubMed
7.
go back to reference Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous cal-cification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997, 386: 78-81. 10.1038/386078a0.CrossRefPubMed Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous cal-cification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997, 386: 78-81. 10.1038/386078a0.CrossRefPubMed
8.
go back to reference Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW: Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007, 72: 202-207. 10.1038/sj.ki.5002178.CrossRefPubMed Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW: Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007, 72: 202-207. 10.1038/sj.ki.5002178.CrossRefPubMed
9.
go back to reference Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wan-ner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003, 361: 827-833. 10.1016/S0140-6736(03)12710-9.CrossRefPubMed Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wan-ner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003, 361: 827-833. 10.1016/S0140-6736(03)12710-9.CrossRefPubMed
10.
go back to reference Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A: Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008, 118: 2555-2562. 10.1161/CIRCULATIONAHA.108.814418.CrossRefPubMed Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A: Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008, 118: 2555-2562. 10.1161/CIRCULATIONAHA.108.814418.CrossRefPubMed
11.
go back to reference Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP: Serum Fetuin-A, Cardiovascular Risk Factors and 6-year Follow-up Outcome in Patients With Coronary Heart Disease. Am J Cardiol. 2010, 105: 1666-1672. 10.1016/j.amjcard.2010.01.342.CrossRefPubMed Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP: Serum Fetuin-A, Cardiovascular Risk Factors and 6-year Follow-up Outcome in Patients With Coronary Heart Disease. Am J Cardiol. 2010, 105: 1666-1672. 10.1016/j.amjcard.2010.01.342.CrossRefPubMed
12.
go back to reference Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER, Reilly MP: Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes. Diabetes Care. 2010, 33: 408-410. 10.2337/dc09-1541.PubMedCentralCrossRefPubMed Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER, Reilly MP: Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes. Diabetes Care. 2010, 33: 408-410. 10.2337/dc09-1541.PubMedCentralCrossRefPubMed
13.
go back to reference Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y: Fetuin-A and atheroclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010, 59: 873-878. 10.1016/j.metabol.2009.10.005.CrossRefPubMed Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y: Fetuin-A and atheroclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010, 59: 873-878. 10.1016/j.metabol.2009.10.005.CrossRefPubMed
14.
go back to reference Stefan N, Weikert C, Ix JH, Fritsche A, Häring HU: Association of lower plasma fetuin-A levels with peripheral arterial disease in type 2 diabetes: response to Eraso et al. Diabetes Care. 2010, 33: e55-10.2337/dc10-0002. author reply e56CrossRefPubMed Stefan N, Weikert C, Ix JH, Fritsche A, Häring HU: Association of lower plasma fetuin-A levels with peripheral arterial disease in type 2 diabetes: response to Eraso et al. Diabetes Care. 2010, 33: e55-10.2337/dc10-0002. author reply e56CrossRefPubMed
15.
go back to reference Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 1995, 67: 1070-1077. 10.1111/j.1523-1755.2005.00172.x.CrossRef Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 1995, 67: 1070-1077. 10.1111/j.1523-1755.2005.00172.x.CrossRef
16.
go back to reference Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005, 28: 164-76. 10.2337/diacare.28.1.164. ReviewCrossRefPubMed Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005, 28: 164-76. 10.2337/diacare.28.1.164. ReviewCrossRefPubMed
17.
go back to reference von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM: Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest. 2010, 40: 95-102. 10.1111/j.1365-2362.2009.02220.x.CrossRefPubMed von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM: Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest. 2010, 40: 95-102. 10.1111/j.1365-2362.2009.02220.x.CrossRefPubMed
18.
go back to reference Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007, 53: 766-72. 10.1373/clinchem.2006.077180.CrossRefPubMed Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007, 53: 766-72. 10.1373/clinchem.2006.077180.CrossRefPubMed
19.
go back to reference Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A: sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res. 2007, 39: 899-902. 10.1055/s-2007-993155.CrossRefPubMed Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A: sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res. 2007, 39: 899-902. 10.1055/s-2007-993155.CrossRefPubMed
20.
go back to reference Meijer JW, Smit AJ, Lefrandt JD, van der Hoeven JH, Hoogenberg K, Links TP: Back to basics in diagnosing diabetic polyneuropathy with the tuning fork!. Diabetes Care. 2005, 28: 2201-2205. 10.2337/diacare.28.9.2201.CrossRefPubMed Meijer JW, Smit AJ, Lefrandt JD, van der Hoeven JH, Hoogenberg K, Links TP: Back to basics in diagnosing diabetic polyneuropathy with the tuning fork!. Diabetes Care. 2005, 28: 2201-2205. 10.2337/diacare.28.9.2201.CrossRefPubMed
21.
go back to reference Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N: Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008, 12 (3): e1765-10.1371/journal.pone.0001765.CrossRef Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N: Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008, 12 (3): e1765-10.1371/journal.pone.0001765.CrossRef
22.
go back to reference Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul study. Circulation. 2006, 113: 1760-1767. 10.1161/CIRCULATIONAHA.105.588723.PubMedCentralCrossRefPubMed Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul study. Circulation. 2006, 113: 1760-1767. 10.1161/CIRCULATIONAHA.105.588723.PubMedCentralCrossRefPubMed
23.
go back to reference Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB: Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008, 57: 2762-2767. 10.2337/db08-0538.PubMedCentralCrossRefPubMed Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB: Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008, 57: 2762-2767. 10.2337/db08-0538.PubMedCentralCrossRefPubMed
24.
go back to reference Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovascular Diabetology. 2005, 4: 4-10.1186/1475-2840-4-4.PubMedCentralCrossRefPubMed Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovascular Diabetology. 2005, 4: 4-10.1186/1475-2840-4-4.PubMedCentralCrossRefPubMed
25.
go back to reference Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein HH, Heemann U, Staessen JA: Association between carotid diameter and the advanced glycation endproduct Nε-Carboxymethyllysine (CML). Cardiovascular Diabetology. 2009, 8: 45-10.1186/1475-2840-8-45.PubMedCentralCrossRefPubMed Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein HH, Heemann U, Staessen JA: Association between carotid diameter and the advanced glycation endproduct Nε-Carboxymethyllysine (CML). Cardiovascular Diabetology. 2009, 8: 45-10.1186/1475-2840-8-45.PubMedCentralCrossRefPubMed
26.
go back to reference Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, Weber C, Ketteler M, Jahnen-Dechent W: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol. 2005, 16: 3357-3364. 10.1681/ASN.2005040365.CrossRefPubMed Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, Weber C, Ketteler M, Jahnen-Dechent W: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol. 2005, 16: 3357-3364. 10.1681/ASN.2005040365.CrossRefPubMed
27.
go back to reference Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG: Fetuin-A and incident diabetes mellitus in older persons.; Health ABC Study. JAMA. 2008, 300: 182-188. 10.1001/jama.300.2.182.PubMedCentralCrossRefPubMed Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG: Fetuin-A and incident diabetes mellitus in older persons.; Health ABC Study. JAMA. 2008, 300: 182-188. 10.1001/jama.300.2.182.PubMedCentralCrossRefPubMed
28.
go back to reference Rittig K, Thamer C, Haupt A, Machann J, Peter A, Balletshofer B, Fritsche A, Haring HU, Stefan N: High Plasma Fetuin-A is associated with Increased Carotid Intima-media Thickness in a Middle-Aged Population. Atherosclerosis. 2009, 207: 341-342. 10.1016/j.atherosclerosis.2009.05.018.CrossRefPubMed Rittig K, Thamer C, Haupt A, Machann J, Peter A, Balletshofer B, Fritsche A, Haring HU, Stefan N: High Plasma Fetuin-A is associated with Increased Carotid Intima-media Thickness in a Middle-Aged Population. Atherosclerosis. 2009, 207: 341-342. 10.1016/j.atherosclerosis.2009.05.018.CrossRefPubMed
29.
go back to reference Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H, Shoji T, Ishimura E, Inaba M, Hara K, Nishizawa Y: Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010, 21: 281-5. 10.1097/MCA.0b013e32832fe5d5.CrossRefPubMed Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H, Shoji T, Ishimura E, Inaba M, Hara K, Nishizawa Y: Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010, 21: 281-5. 10.1097/MCA.0b013e32832fe5d5.CrossRefPubMed
30.
go back to reference Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004, 350: 1387-1397. 10.1056/NEJMoa032804.CrossRefPubMed Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004, 350: 1387-1397. 10.1056/NEJMoa032804.CrossRefPubMed
31.
go back to reference von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008, 29: 1307-1315. 10.1093/eurheartj/ehn135.CrossRefPubMed von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008, 29: 1307-1315. 10.1093/eurheartj/ehn135.CrossRefPubMed
Metadata
Title
Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy
Authors
Marcel Roos
Dimitrios Oikonomou
Maximilian von Eynatten
Peter B Luppa
Uwe Heemann
Jens Lutz
Marcus Baumann
Peter P Nawroth
Angelika Bierhaus
Per M Humpert
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-48

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.